Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes;Czy agoniści dopaminy sa alternatywa dla lewodopy we wczesnym okresie choroby Parkinsona? Tak

Neurologia i Neurochirurgia Polska

Volumn 41, Issue 2 SUPPL. 1, 2007, Pages

  Szczudlik, Andrzej ^a   Rudzińska, Monika ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY HOSPITAL IN KRAKOW   (Poland)

Author keywords

Dopamine agonist; Early stage of Parkinson's disease; Treatment

Indexed keywords

AMINO ACID; BROMOCRIPTINE MESILATE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; FREE RADICAL; LEVODOPA; PERGOLIDE MESILATE; PRAMIPEXOLE; ROPINIROLE;

AEROBIC METABOLISM; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; DYSKINESIA; EVIDENCE BASED MEDICINE; HUMAN; MOTOR DYSFUNCTION; OXIDATIVE STRESS; PARKINSON DISEASE; RISK REDUCTION;

ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; HUMANS; LEVODOPA; PARKINSON DISEASE; RECEPTORS, DOPAMINE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34248573543     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Olanow C.W., Watts R.L., Koller W.C. Algorytm postepowania w chorobie Parkinsona. Prusiński A. [red. wyd. pol.]. Wyd. Czelej, Lublin 2001.
2. Olanow C.W. The role of dopamine agonists in the treatment of early Parkinson's disease. Neurology 2002; 58 (sup1. 1): S33-41.
3. Montastruc J.L., Rascol O., Senard J.M. i wsp. A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 1994; 57: 1034-1038.
4. Safety and efficacy of pramipexole, in early Parkinson disease: a randomized dose-ranging study. Parkinson Study Group. JAMA 1997; 278: 125-130.
5. Shannon K.M., Bennett J.P. Jr, Friedman J.H. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group. Neurology 1997; 49: 724-728.
6. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease - a randomized controlled trial. JAMA 2000; 284: 1931-1938.
7. Parkinson Study Group. A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 2000; 23: 34-44.
8. Adler C.H., Sethi K.D., Hauser R.A. i wsp. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997; 49: 393-399.
9. Rascol O., Brooks D.J., Korczyn A.D. i wsp. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-1491.
10. Barone P, Bravi D., Bermejo-Pareja F. i wsp. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study Pergolide Monotherapy Study Group. Neurology 1999; 53: 573-579.
11. Rinne U. K., Bracco F., Chouza C. i wsp. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998; 55 (supl. 1): 23-30.
12. Hubble J.P. Long-term studies of dopamine agonist. Neurology 2002; 58 (supl. 1): S42-50.
13. Olanow C.W., Alberts M., Stajich J. i wsp. A randomized blinded study of Iow dose bromocriptine versus Iow dose carbidopa/levodopa in untreated Parkinson patients. W: Fahn S., Marsden D., Calne D., Goldstein M. [red.]. Recent developments in Parkinson's disease. T. II. Macmillan Health Care, New York 1987, ss. 201-208.
14. Rascol O., Brooks D.J., Brunt E.R. i wsp. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998; 13: 39-45.
15. Bedard P.J., Di Paolo T, Falardeau P. i wsp. Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H] spiperone binding. Brain Res 1986; 379: 294-299.
16. Pearce R.K., Banerji T., Jenner P. i wsp. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset. Mov Disord 1998; 13: 234-241.
17. Bedard P.J., Gomez-Mancilla B., Blanchet P. i wsp. Dopamine agonists as first line therapy of parkinsonism in MPTP monkeys. W: Olanow C.W., Obeso J.A. [red.]. Dopamine agonists in early Parkinson's disease. Well Medical, Kent 1997, ss. 101-113
18. Hely M.A., Morris J.G., Reid W.G. i wsp. The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903-910.
19. Rinne U.K. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987; 37: 826-828.
20. Corrigan M.H., Denahan A.Q., Wright C.E. i wsp. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11: 58-65.
21. Blanchet P.J., Calon F., Martel J.C. i wsp. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995; 272: 854-859.